674 related articles for article (PubMed ID: 36300110)
1. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy.
Jin Z; Sun X; Wang Y; Zhou C; Yang H; Zhou S
Front Immunol; 2022; 13():1018903. PubMed ID: 36300110
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance.
Jiang T; Chen X; Ren X; Yang JM; Cheng Y
Drug Resist Updat; 2021 May; 56():100752. PubMed ID: 33765484
[TBL] [Abstract][Full Text] [Related]
4. Challenges and opportunities for cancer stem cell-targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell-dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes.
Alqarni A; Jasim SA; Altalbawy FMA; Kaur H; Kaur I; Rodriguez-Benites C; Deorari M; Alwaily ER; Al-Ani AM; Redhee AH
J Biochem Mol Toxicol; 2024 Jun; 38(6):e23719. PubMed ID: 38764138
[TBL] [Abstract][Full Text] [Related]
5. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
6. An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy.
Li YR; Yu Y; Kramer A; Hon R; Wilson M; Brown J; Yang L
Cells; 2022 May; 11(9):. PubMed ID: 35563889
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.
Zhang M; Kim JA; Huang AY
Front Immunol; 2018; 9():341. PubMed ID: 29535722
[TBL] [Abstract][Full Text] [Related]
8. Target tumor microenvironment by innate T cells.
Li YR; Wilson M; Yang L
Front Immunol; 2022; 13():999549. PubMed ID: 36275727
[TBL] [Abstract][Full Text] [Related]
9. Improving Breast Cancer Responses to Immunotherapy-a Search for the Achilles Heel of the Tumor Microenvironment.
Jenkins S; Wesolowski R; Gatti-Mays ME
Curr Oncol Rep; 2021 Mar; 23(5):55. PubMed ID: 33755828
[TBL] [Abstract][Full Text] [Related]
10. Immunologic tumor microenvironment modulators for turning cold tumors hot.
Khosravi GR; Mostafavi S; Bastan S; Ebrahimi N; Gharibvand RS; Eskandari N
Cancer Commun (Lond); 2024 May; 44(5):521-553. PubMed ID: 38551889
[TBL] [Abstract][Full Text] [Related]
11. ADGRE5-centered Tsurv model in T cells recognizes responders to neoadjuvant cancer immunotherapy.
Li J; Meng Z; Cao Z; Lu W; Yang Y; Li Z; Lu S
Front Immunol; 2024; 15():1304183. PubMed ID: 38343549
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
Wang Z; Wang Y; Gao P; Ding J
Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
[TBL] [Abstract][Full Text] [Related]
13. The Single-Cell Level Perspective of the Tumor Microenvironment and Its Remodeling by CAR-T Cells.
Gao S; Sugimura R
Cancer Treat Res; 2022; 183():275-285. PubMed ID: 35551664
[TBL] [Abstract][Full Text] [Related]
14. Targeting WEE1/AKT Restores p53-Dependent Natural Killer-Cell Activation to Induce Immune Checkpoint Blockade Responses in "Cold" Melanoma.
Dinavahi SS; Chen YC; Punnath K; Berg A; Herlyn M; Foroutan M; Huntington ND; Robertson GP
Cancer Immunol Res; 2022 Jun; 10(6):757-769. PubMed ID: 35439317
[TBL] [Abstract][Full Text] [Related]
15. Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies.
Li YR; Halladay T; Yang L
J Biomed Sci; 2024 Jan; 31(1):5. PubMed ID: 38217016
[TBL] [Abstract][Full Text] [Related]
16. Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity.
Mansouri S; Heylmann D; Stiewe T; Kracht M; Savai R
Elife; 2022 Sep; 11():. PubMed ID: 36074553
[TBL] [Abstract][Full Text] [Related]
17. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptors for the Tumour Microenvironment.
Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
[TBL] [Abstract][Full Text] [Related]
19. A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity.
Kim K; Yang WH; Jung YS; Cha JH
BMB Rep; 2020 Nov; 53(10):512-520. PubMed ID: 32731915
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.
Barnestein R; Galland L; Kalfeist L; Ghiringhelli F; Ladoire S; Limagne E
Oncoimmunology; 2022; 11(1):2120676. PubMed ID: 36117524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]